These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 3901894)

  • 1. The role of complement in opsonization of GBS.
    Edwards MS; Kasper DL; Nicholson-Weller A; Baker CJ
    Antibiot Chemother (1971); 1985; 35():170-89. PubMed ID: 3901894
    [No Abstract]   [Full Text] [Related]  

  • 2. Methods of assessment and importance of opsonic activity for GBS.
    Hill HR; Shigeoka AO; Rote NS; Allred CD; Hemming VG
    Antibiot Chemother (1971); 1985; 35():157-69. PubMed ID: 3901892
    [No Abstract]   [Full Text] [Related]  

  • 3. Absolute requirement for complement in monoclonal IgM antibody-mediated protection against experimental infection with type III group B streptococci.
    Shigeoka AO; Jensen CL; Pincus SH; Hill HR
    J Infect Dis; 1984 Jul; 150(1):63-70. PubMed ID: 6379061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of complement and antibody in opsonophagocytosis of type II group B streptococci.
    Baker CJ; Webb BJ; Kasper DL; Edwards MS
    J Infect Dis; 1986 Jul; 154(1):47-54. PubMed ID: 3519791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group-B streptococcus--profile of an organism.
    Ross PW
    J Med Microbiol; 1984 Oct; 18(2):139-66. PubMed ID: 6387125
    [No Abstract]   [Full Text] [Related]  

  • 6. A new flow-cytometry-based opsonophagocytosis assay for the rapid measurement of functional antibody levels against Group B Streptococcus.
    Fabbrini M; Sammicheli C; Margarit I; Maione D; Grandi G; Giuliani MM; Mori E; Nuti S
    J Immunol Methods; 2012 Apr; 378(1-2):11-9. PubMed ID: 22309986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody-independent classical pathway-mediated opsonophagocytosis of type Ia, group B streptococcus.
    Baker CJ; Edwards MS; Webb BJ; Kasper DL
    J Clin Invest; 1982 Feb; 69(2):394-404. PubMed ID: 7035495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic variability of X-protein expression by mastitis-causing Streptococcus agalactiae of serotype NT/X and opsonic activities of specific antibodies.
    Rainard P; Sarradin P; Poutrel B
    Microb Pathog; 1994 May; 16(5):359-72. PubMed ID: 7815919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of antibody and complement in opsonization of group B streptococci.
    Shigeoka AO; Hall RT; Hemming VG; Allred CD; Hill HR
    Infect Immun; 1978 Jul; 21(1):34-40. PubMed ID: 101462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibody preparations for immunotherapy of experimental GBS infection.
    Shigeoka AO; Pincus SH; Rote NS; Pritchard DG; Santos JI; Hill HR
    Antibiot Chemother (1971); 1985; 35():254-66. PubMed ID: 3901902
    [No Abstract]   [Full Text] [Related]  

  • 11. Opsonization of Streptococcus agalactiae of bovine origin by complement and antibodies against group B polysaccharide.
    Rainard P; Boulard C
    Infect Immun; 1992 Nov; 60(11):4801-8. PubMed ID: 1398991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variations in the opsonic requirements of group B streptococcus type III.
    Hastings MJ; Easmon CS
    Br J Exp Pathol; 1981 Oct; 62(5):519-25. PubMed ID: 7028075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a multiplexed opsonophagocytic killing assay (MOPA) for group B Streptococcus.
    Choi MJ; Noh JY; Cheong HJ; Kim WJ; Lin SM; Zhi Y; Lim JH; Lim S; Seo HS; Song JY
    Hum Vaccin Immunother; 2018 Jan; 14(1):67-73. PubMed ID: 28933634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neonatal cellular and humoral immunity to group B streptococci.
    Hill HR; Shigeoka AO; Hall RT; Hemming VG
    Pediatrics; 1979 Nov; 64(5 Pt 2 Suppl):787-94. PubMed ID: 388335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of differences in antibody and complement requirements on phagocytic uptake and intracellular killing of "c" protein-positive and -negative strains of type II group B streptococci.
    Payne NR; Kim YK; Ferrieri P
    Infect Immun; 1987 May; 55(5):1243-51. PubMed ID: 3552996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular and humoral aspects of host defense mechanisms against GBS.
    Gotoff SP; Boyer KM
    Antibiot Chemother (1971); 1985; 35():142-56. PubMed ID: 3901891
    [No Abstract]   [Full Text] [Related]  

  • 17. The role of complement in the opsonization of mucoid and non-mucoid strains of Pseudomonas aeruginosa.
    Baltimore RS; Shedd DG
    Pediatr Res; 1983 Dec; 17(12):952-8. PubMed ID: 6419197
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement in neonatal infections: an overview.
    Edwards MS
    Pediatr Infect Dis; 1986; 5(3 Suppl):S168-70. PubMed ID: 3520500
    [No Abstract]   [Full Text] [Related]  

  • 19. Deficient classical complement pathway activity in newborn sera.
    Edwards MS; Buffone GJ; Fuselier PA; Weeks JL; Baker CJ
    Pediatr Res; 1983 Aug; 17(8):685-8. PubMed ID: 6412204
    [No Abstract]   [Full Text] [Related]  

  • 20. [Antibody titer against B-streptococci in human gamma globulin].
    Fox EN; Schmidt BL; Collins MS
    MMW Munch Med Wochenschr; 1981 Nov; 123(46):1743-4. PubMed ID: 6171730
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.